Trial Profile
An open-label study of the safety and tolerability of PEGASYS alone and in combination with ribavirin in patients with chronic hepatitis C.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jun 2010
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Roche
- 26 Feb 2010 New trial record